TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Intervention About Breastfeeding and Complementary Feeding in Adolescent Mothers and Their Grandmothers
Brief Summary: The purpose of this study is to determine whether counseling sessions on breastfeeding for adolescent mothers and their grandmothers in the maternity ward and at home are effective in to improve the exclusive and total breastfeeding rates during the first six month, as well as the convenient timing of supplementary feeding introduction.


Options:
A: Inclusion Criteria:

Maternal/infant pairs Infant under 2 months of age Mother English speaking

Exclusion Criteria:

History of Neonatal ICU stay in infant Gestation less than 37 weeks in infant chronic disease in infant known genetic disorder in infant foster care placement in infant
B: Inclusion Criteria:

* Able to consume solid food
* Allergy to eggs and/or severe eczema
* Informed consent obtained from parent or guardian.

Exclusion Criteria:

* Clinically significant chronic illness. Participants with eczema or recurrent wheeze are not excluded.
* Positive skin prick test for peanut allergen with a wheel diameter greater than 4 mm in the presence of a negative saline control
* Previous or current consumption of peanut protein that exceeds 0.2 g of peanut protein on at least one occasion or 0.5 g over a single week
* Investigator-suspected allergy to peanut protein
* Investigator-suspected allergy to peanut protein in care provider or current household member.
* Diagnosis of persistent asthma
* ALT (SGPT) or bilirubin greater than 2 times the upper limit of age-related normal value
* BUN or creatinine greater than 1.25 times the upper limit of age-related normal value
* Platelet count less than 100,000/mL, hemoglobin less than 9 g/dL, or investigator-suspected immunocompromise
* Unwillingness or inability to comply with study requirements and procedures
C: Inclusion Criteria:

* Adolescent mothers
* Mothers living in the city of Porto Alegre
* Healthy nontwin newborns with birth weight equal or greater than 2500g

Exclusion Criteria:

* Mothers living with mother-in-law
* Mother-infant pairs that were unable to stay together due to a health concern in either the mother or infant
* Mammaplasty reductive
D: Inclusion Criteria:

* Mothers booked for delivery in Dunedin, New Zealand

Exclusion Criteria:

* Women booked after 34 weeks gestation,
* Identified congenital abnormality likely to affect feeding and/or growth
* Home address outside of metropolitan Dunedin or Invercargill,
* Families who are likely to shift out of metropolitan Dunedin or Invercargill in the next 2 years.
* Unable to communicate in English or te reo Maori.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prospective, Double-Blinded, Randomised Controlled Trial of Doppler-Optimised Fluid Balance in Elective Colectomy Within an ERAS Protocol
Brief Summary: Perioperative fluid management has been historically dictated by outdated, contradictory concepts. Excessive or inadequate fluid administration around surgery is deleterious and hence goal-directed fluid therapy using Oesophageal Doppler-derived cardiac indices is preferable to optimize tissue perfusion. Previous studies in this area have been hampered by lack of standardization in other aspects of perioperative care and none have explored the impact of individualized fluid therapy on post-operative fatigue.The investigators proposed a study involving 80 patients having open/ laparoscopic colonic surgery to investigate the effect of Oesophageal Doppler guided fluid administration intraoperatively compared to current best practice of fluid restriction. The investigators have an optimized peri-operative care pathway established at the Manukau Surgical Centre (MSC), Middlemore Hospital. All patients will be cared for under the Enhanced Recovery After Surgery (ERAS) multimodal care plan therefore ensuring that all other aspects of care besides intraoperative fluid administration remain homogenous. Outcomes will include post-operative recovery, clinical outcomes as well as physiological data with follow-up to 30 days.


Options:
A: Inclusion Criteria:

* Medico-surgical pre-operative decision of post-operative ICU admission (because of co-morbidities or/and the surgical procedure)
* Age \> 18 yr
* Elective surgery

Exclusion criteria:

* No informed consent
* Cardiac arrhythmias
* Body mass index \> 40
* Patients undergoing surgery with an open thorax
* Patients undergoing neurosurgery
* Enrolment in any other protocol
B: Inclusion Criteria:

* Major intraabdominal surgery

Exclusion Criteria:

* Age \< 18 years
* Pregnancy
* Body mass index \> 35 kg/m2
* Emergency surgery
* Coagulopathy
* Sepsis or Systemic inflammatory response syndrome (SIRS)
* Hepatic failure (prothrombin ratio \< 50%, factor V \< 50%)
* Contraindication for epidural analgesia
C: Inclusion Criteria:

* Laparoscopic and/or robotic elective abdominal surgery( colorectal, gynecological, urological)

Exclusion Criteria:

* Intraoperative invasive monitoring (arterial line)
* Open colorectal surgery (laparotomy)
* Emergency surgery
* Expected intraoperative blood loss greater than 1000ml
* Arrhythmia (e.g. atrial fibrillation)
D: Inclusion Criteria:

* consecutive patients undergoing open/ laparoscopic colonic resection at Manukau surgical Centre (MSC)or North Shore Hospital, Auckland.

Exclusion Criteria:

* severe oesophageal disease
* recent oesophageal or upper airway surgery
* moderate or severe aortic valve disease as proven by echocardiogram
* documented bleeding diathesis
* preoperative steroid use
* cognitive impairment
* ASA\>3
* patient choice.
* rectal tumour (defined as less an 15cm from anal verge on preop investigations)
* creation of stoma
* difficulty in obtaining reliable measurements from ODM

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Vitamin D Supplementation and CD4 Count in HIV-Infected Children
Brief Summary: To find out if vitamin D supplementing can lead to an improvement in immunological status in HIV-infected children as part of routine clinical care


Options:
A: Inclusion Criteria: Singleton, live born infants born to HIV-infected women Exclusion Criteria: Infants with multiple congenital abnormalities
B: Inclusion Criteria:

1. 1 to 11 month old infants living in the study area
2. caretakers are willing to give consent to take part in the study

Exclusion Criteria:

1. the family is likely to migrate out of the study area within the next 18 months
2. the child has been diagnosed with rickets or known to have received a course of vitamin D treatment in the past 3 monDths.
3. Child with Kwashiorkor or Marasmus.
C: Inclusion Criteria:

* HIV-infected children as defined by ≥ 2 positive HIV DNA PCRs and/or HIV cultures of blood for children less than 18 months of age, or by positive screening and confirmatory serologic testing in those older than 18 months of age
* Stable HIV disease, defined by the absence of change in HIV clinical or immunologic category during the preceding 6 month period, prior to commencing the study
* Age 3 years through 18 years
* Voluntary informed consent

Exclusion Criteria:

* Any antiretroviral medication change in the 6 months prior to the study, or any anticipated antiretroviral medication change during the duration of the study
* Active participation in another treatment trial
* Serum calcium \< 2mmol/L at baseline
D: Inclusion Criteria:

* Age 2-17 years
* AD rated 10-72 by EASI scale
* Wintertime onset or exacerbation of AD

Exclusion Criteria:

* Active skin infection
* History of summertime onset or exacerbation of AD
* History of underlying illness causing immunosuppression within the past 2 years (eg. hematologic malignancies)
* Medications causing iatrogenic immunosuppression (eg. cyclosporine; azathioprine, oral steroids) taken within the past month
* Parathyroid disease
* Acute or chronic renal disease
* Hypercalcemia or hypocalcemia
* Thyroid disease
* History of osteomalacia or Paget's disease of bone
* History of malabsorption (eg cystic fibrosis)
* Planned trip to sunny climate during the one-month study

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Vitamin D Supplementation and CD4 Count in HIV-Infected Children
Brief Summary: To find out if vitamin D supplementing can lead to an improvement in immunological status in HIV-infected children as part of routine clinical care


Options:
A: Inclusion Criteria:

* Men and women, age 18 to 60 years inclusive
* At least two positive sputum smears for tuberculosis
* Intention to stay in Dar-es-Salaam for at least 2 years after the start of TB therapy
* Subjects who grant informed consent to participation

Exclusion Criteria:

* Karnofsky score \< 40%
* Hemoglobin \< 8.5 g/dl
* Having had treatment for TB exceeding 4 weeks in the last 5 years
* Pregnant women
B: Inclusion Criteria:

1. HIV seropositive diagnosed with standard techniques
2. Age for PA Group: 5.0 to 24.9 y
3. Age for BA Group: 15.0 to 24.9 y
4. In usual state of good health (no hospitalizations, emergency room or unscheduled acute illness visits for 2 weeks prior to enrollment)
5. Subject and/or family commitment to the 12-month study

Exclusion Criteria:

1. Other chronic health conditions that may affect growth, dietary intake, and/or nutritional status
2. Pregnancy
3. Participation in another HIV intervention study with impact on 25D serum concentrations
4. Use of vit D3 supplementation for the purpose of treating vit D deficiency
5. Use of vit D3 supplementation not part of a prescribed treatment plan for vit D deficiency (subjects willing to discontinue supplementation will become eligible after a minimum of a 2 month washout period)
6. Non-English Speaking
C: Inclusion Criteria:

* HIV-infected children as defined by ≥ 2 positive HIV DNA PCRs and/or HIV cultures of blood for children less than 18 months of age, or by positive screening and confirmatory serologic testing in those older than 18 months of age
* Stable HIV disease, defined by the absence of change in HIV clinical or immunologic category during the preceding 6 month period, prior to commencing the study
* Age 3 years through 18 years
* Voluntary informed consent

Exclusion Criteria:

* Any antiretroviral medication change in the 6 months prior to the study, or any anticipated antiretroviral medication change during the duration of the study
* Active participation in another treatment trial
* Serum calcium \< 2mmol/L at baseline
D: Inclusion Criteria:

Subject, parent, or legal guardian able and willing to provide informed consent/assent.

Subject able and willing to comply with requirements of study HIV-infected subjects must have diagnosis confirmed with one or more of the following tests: 1) HIV DNA Polymerase chain reaction or HIV culture performed at any age; 2) Age \>18 months, licensed ELISA with confirmatory Western Blot.

Exclusion Criteria:

Patients with history of atraumatic fractures, known renal or liver disease, known malabsorption syndrome, or inflammatory bowel disease.

Use of corticosteroids, exculding inhaled steroids (current or within past 6 months) Current use of anticonvulsant drug Daily cigarette smoking Daily consumption of alcohol containing beverages Current use of tenofovir

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency.
Brief Summary: This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.


Options:
A: Inclusion Criteria:

* Symptoms of Overactive Bladder (OAB) (frequency/urgency) with urinary incontinence for at least 6 months
* Inadequate response or limiting side effects with anticholinergics for the treatment of OAB

Exclusion Criteria:

* Overactive Bladder caused by neurological condition
* Patient has predominance of stress incontinence
* Use of anticholinergics or other medications to treat OAB symptoms in the 7 days prior to screening
* Previous use of solifenacin
* History or evidence of pelvic or urological abnormality
* Previous use of any botulinum toxin of any serotype for any urological condition
* Previous use of any botulinum toxin of any serotype for any non-urological condition within 12 weeks of randomization
* Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis
B: Inclusion Criteria:

* Mean urinary frequency of \>=8 micturitions per 24 hours as verified by the screening bladder diary prior to Start of Placebo run in visit (Visit 2)
* Mean number of micturition related urgency episodes \>=3 per 24 hours as verified by the screening bladder diary prior to Start of Placebo run in /Visit 2 (Urgency episodes are defined as those with Urinary Sensation Scale rating \>=3)
* Mean number of micturition related nocturnal urgency episodes \>=2 but no more than 8 episodes per 24 hours as verified by the bladder diary at Visit 2 (nocturnal urgency episodes are defined as those with Urinary Sensation Scale rating of \>3 recorded in the bed time section of the bladder diary)

Exclusion Criteria:

* A known recent history or previous diagnosis of any sleep disorder such as obstructive sleep apnea, primary insomnia, periodic limb movement, parasomnia
* Nocturia due to other underlying uncontrolled conditions, such as congestive heart failure, diabetes mellitus, diabetes insipidus, polyuria of any cause, etc.
C: Inclusion Criteria:

* Male or female ≥65 years old.
* Overactive bladder symptoms for at least 3 months prior to study start.
* Eight or more micturitions per 24 hours as confirmed by diary records

Exclusion Criteria:

* Predominant Stress Urinary Incontinence
* Active or recurrent bladder infections
* Other bladder and genital conditions that could be the predominant cause of symptoms or interfere with treatment assessment and success.
D: Inclusion Criteria:

* Overactive bladder syndrome

Exclusion Criteria:

* Less than 8 micturitions in 24 hours

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study
Brief Summary: The purpose of this study is to determine the effects of the anticholinesterase drug donepezil on sleep apnea patients. Sleep structure and respiratory parameters will be analyzed by polysomnography.


Options:
A: Inclusion Criteria:

* Diagnosis of Alzheimer's disease based on the probability criteria of the Alzheimer's Disease and Related Disorders Association
* Rated 1 and 2 (mild to moderate level) on the Brazilian version of the Clinical Dementia Rating

Exclusion Criteria:

* Other causes of dementia
* Other severe medical or psychiatric disease
* Clinical indication of psychoactive drugs other than experimental drug
B: Inclusion Criteria:

* diagnosis of obstructive sleep apnea according to American Academy of Sleep Medicine criteria

Exclusion Criteria:

* body mass index \> 40
* use of psychoactive drugs
* presence of neurological, cardiological and pulmonary diseases
C: Inclusion Criteria:

* Epworth \<10
* Apnea-Hypopnea Index ≥20

Exclusion Criteria:

* Presence of any chronic disease
* Presence of cardiovascular disease
* Refusal to sign informed consent
* Drug addiction and/or alcoholism
D: Inclusion Criteria:

* Having previous diagnosis of sleep apnea not treated with Continuous Positive Airway Pressure (CPAP) or presenting clinical symptoms of sleep apnea
* Overweight or obese, with BMI \>= 25 kg/m² and \< 40 kg/m².
* Known moderate hypertriglyceridemia, with fasting Triglycerides level \>= 2.0 and \< 6.0 mmol/L within 3 months before the inclusion.

Exclusion Criteria:

* indication for immediate CPAP
* other known endocrine disease, except treated and adequately controlled hypothyroidism
* renal failure or plasma creatinine level \>130 µmol/L
* current chronic liver disease or ALanine Amino Transferase (ALT)\> 2 times the upper normal limit (UNL)
* symptomatic gallbladder disease
* known muscular disease or creatine phosphokinase (CK) \> 3 times UNL.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Prospective Randomized Double-masked Evaluation of Treatment Duration of the UVX System for Treating Infectious Keratitis
Brief Summary: This study is comparing 45 minute and 30 minute treatment durations with the UVX corneal cross linking system to treat corneal infections.


Options:
A: Inclusion Criteria:

* fungal keratitis documented by culture or confocal scanning without any previous treatment

Exclusion Criteria:

* Previous treatment
* Thinning at presentation
* Perforation
* Associated with other microbial or viral keratitis
B: Inclusion Criteria:

* diagnosis of infectious keratitis

Exclusion Criteria:

* corneal ulcer that has perforated
* corneal ulcer that has produced a descemetocele
* women who are pregnant or breastfeeding
* patients who are immunocompromised or unwilling or unable to comply with a medication regimen
C: Inclusion Criteria:

* Subjects with infectious keratitis (initial or refractory to treatment) including bacterial or mycotic keratitis with size larger than 3 mm

Exclusion Criteria:

* herpetic keratitis
* Acanthamoeba keratitis
* pregnancy
* endophthalmitis
* systemic immunosuppression
D: Inclusion Criteria:

* Willing and able to provide written informed consent
* Willing and able to comply with study assessments for the full duration of the study
* Age ≥ 18 years
* Candidate for a Boston Keratoprosthesis / Cornea transplant
* In generally good stable overall health
* Patients with an eye at risk for a cornea sterile ulcer which includes:

  * Autoimmune diseases (mucus membrane pemphigoid, Stevens-Johnson syndrome, systemic lupus erythematosis, rheumatoid arthritis, or other autoimmune diseases); OR
  * History of previous sterile cornea ulceration requiring a cornea transplant

Exclusion Criteria:

* Age \< 18 years
* Inability to provide written informed consent and comply with study assessments for the full duration of the study
* No or minimal tear production with evidence of keratinization of the bulbar conjunctiva
* Corneal or ocular surface infection within 30 days prior to study entry
* Ocular or periocular malignancy
* Inability to wear a contact lens due to lid abnormalities or shortened fornix
* Signs of current infection, including fever and current treatment with antibiotics
* Pregnancy (positive pregnancy test) or lactating
* Participation in another simultaneous interventional medical investigation or trial

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: SMS Turkey: Harnessing the Power of TXT Messaging to Promote Smoking Cessation
Brief Summary: The purpose of this study is to develop and test a text messaging-based smoking cessation program for adults who are currently smoking and want to quit, living in Turkey.


Options:
A: Inclusion Criteria:

1. Current patient at one of two SLR CCC clinics with a designated physician (had intake visit and enrolled into clinic)
2. Age 18 years or older;
3. Current or regular smoker (\>5 cigarettes per day);
4. Carbon Monoxide (CO) monitor reading of \>8 ppm;
5. Willingness to set a quit date;
6. Able to conduct activities in English;
7. Ability to provide informed consent;
8. Willingness to carry/use a cell phone; AND
9. Eligible to take varenicline as determined by the patient's primary care provider

Exclusion Criteria:

1. Unstable cardiovascular disease (e.g. uncontrolled blood pressure, unstable angina, or myocardial infarction in the past 4 weeks);
2. Current homicidal or suicidal ideation, history of suicidal ideation, or history of psychosis;
3. Has a serious or untreated psychiatric illness (major depression, bipolar or schizophrenia);
4. Severe renal impairment (defined as having a creatinine clearance \< 30mL/min);
5. Currently using smokeless tobacco;
6. Currently using FDA-approved smoking cessation medication or other smoking cessation treatment and or participating in another smoking cessation program;
7. Active drug use identified by a score of 6 or above on DAST-10 Drug Abuse Screening Test;
8. Alcohol dependence or risk drinking identified by a score of 5 or above for men and 4 or above for women on AUDIT-C Alcohol Use Disorders Identification Test
9. Pregnant or nursing; AND/OR
10. Has a cognitive impairment that would preclude giving consent.
B: Inclusion Criteria:

* 18 years of age or older
* Currently smoking every day
* Owning a TXT-capable cell phone
* Sent or received TXT messages at least once in the past year
* Living in Ankara (to ease technology support if necessary)
* Agreement to set quit day in 15 days from enrollment date
* Agreement to verification of smoking cessation using a carbon monoxide breath monitor

Exclusion Criteria:

• No chronic disease.
C: Inclusion Criteria:

* Age 18 to 35
* Current daily smoker
* Has a cell phone with text messaging capability
* Uses text messaging at least once monthly
* Interested in quitting smoking
* Willing to set a quit date within the next 30 days
* Has access to a physician

Exclusion Criteria:

* Does not read and speak English with adequate comprehension
* Is currently participating in a smoking cessation program
* Concurrent drug/alcohol abuse
* Mental health issues that would interfere with study compliance
D: Inclusion Criteria:

* Participant between 18 t0 30 years old smoking 10 or more cigarretes at day
* To have a smarthphone (Android, ios Ihpone, ios Ipad)
* Normal and high motivation for smocking cessation

Exclusion Criteria:

* To have other addictions
* Participants with Blackberry smarthphone

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: SMS Turkey: Harnessing the Power of TXT Messaging to Promote Smoking Cessation
Brief Summary: The purpose of this study is to develop and test a text messaging-based smoking cessation program for adults who are currently smoking and want to quit, living in Turkey.


Options:
A: Inclusion Criteria:

* Age 18 to 35
* Current daily smoker
* Has a cell phone with text messaging capability
* Uses text messaging at least once monthly
* Interested in quitting smoking
* Willing to set a quit date within the next 30 days
* Has access to a physician

Exclusion Criteria:

* Does not read and speak English with adequate comprehension
* Is currently participating in a smoking cessation program
* Concurrent drug/alcohol abuse
* Mental health issues that would interfere with study compliance
B: Inclusion Criteria:

* adult smokers
* with an information and consent form completed
* agreed to participate in the study
* get a Smartphone and be willing to use applications
* wanting stop smoking (in short, medium or long terms).

Exclusion Criteria:

* refusal to participate in the study
C: Inclusion Criteria:

* 18 years of age or older
* Currently smoking every day
* Owning a TXT-capable cell phone
* Sent or received TXT messages at least once in the past year
* Living in Ankara (to ease technology support if necessary)
* Agreement to set quit day in 15 days from enrollment date
* Agreement to verification of smoking cessation using a carbon monoxide breath monitor

Exclusion Criteria:

• No chronic disease.
D: Inclusion Criteria:

Hong Kong residents aged 18 or above

* Smoke at least 1 cigarette per day in the past 3 months
* Able to communicate in Cantonese
* Exhaled carbon monoxide (CO) 4 ppm or above, assessed by a validated CO smokerlyzer
* Have Intention to quit / reduce smoking

Exclusion Criteria:

* Smokers who have difficulties (either physical or cognitive condition) to communicate
* Currently following other smoking cessation programs

Answer: C